American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time.  Stolbach, A. I., Mazer-Amirshahi, M. E., Nelson, L…

USA: National Harm Reduction Coalition - Online Learning https://harmreduction.org/our-work/training-capacity-building/online-training-institute/

Clinical Considerations for Engagement and Retention of Nonabstinent Patients in Care.  Boyle MP, Gibson E, Lien J, Manages S, Mohr S, Ryan C, Tsai G.  J Addict Med. 2025 Feb 5. doi: 10.1097/ADM.0000000000001455. Epub ahead of print. PMI…

Engagement and Retention of Nonabstinent Patients in Substance Use Treatment: Clinical Consideration for Addiction Treatment Providers.  American Society of Addiction Medicine. October 2024. Accessed [28.02.2025].  https://www.asam.org/…

Towards opioid access without excess Rosa, William E et al. The Lancet Public Health, Volume 0, Issue 0  https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00035-0/fulltext

Ventizolve (Naloxon) 1,26 mg Nasenspray, Lösung im Einzeldosisbehältnis (Gebrauchsinformation: Information für Anwender) Ventizolve (Naloxon) - Packungsbeilage.pdf